Immunoassays for the detection or quantitation of an antigen can be categorised into those in which no labelled reactant is required, those employing labelled antigen, and others in which specific antibodies are labelled.
NON-LABELLED IMMUNOASSAYS
Several immunoassay techniques do not require the use of a labelled reactant.f Some depend on the precipitation line which forms in a gel support when a protein antigen comes into contact with its specific antibody while other manual and automated procedures depend, for end-point detection, on the increase in light scattering produced. Despite their extensive and rapidly increasing use, non-labelled techniques are limited to the assay of proteins and other large molecules present at relatively high concentrations, since only in such circumstances are the resultant antigen : antibody complexes sufficiently large to form a precipitin line or scatter light. Additional disadvantages include the need for relatively large amounts of monospecific antisera; problems with very turbid or haemolysed samples; and the possibility of erroneous results in the presence of antigen excess-due to the prozone phenomenon.
IMMUNOASSAYS EMPLOYING LABELLED ANTIGEN
The use of antigen labelled with a radioisotope, by Yalow and Berson in a radioimmunoassay (RIA) for insulin," proved an important milestone. It made possible the assay of haptens (such as drugs and the thyroid and steroid hormones) as well as proteins; resulted in a million-fold increase in sensitivity; removed the need for monospecific antisera and markedly reduced the amounts of antisera required; avoided the problem of antigen excess; and enabled the assay of haemolysed and turbid samples. In the same year, Ekins had recognised the wider implication of this approach and developed techniques for both thyroxine (T 4 ) 4 and vitamin B 12 5 employing 253 Basis and types of immunoassay As its name implies, an immunoassay is an analytical procedure based on the reaction between an antigen and a specific antibody, which obeys the Law of Mass Action:
The immediate future of laboratory practice will continue to lie with immunoassay because of its specificity, potential sensitivity, practicality and, in particular, wide applicability. There has been considerable recent interest in the use of fluorescent molecules as a label for immunoassay purposes. This review attempts to explain simply the basis of immunoassay with particular reference to fluoroimmunoassay (PIA) and immunofluorometric analysis (IFMA); to con-pare the advantages and disadvantages of fluorescent labels as compared with radioisotopes and other non-isotopic alternatives; and to consider the many different analytical approaches made possible by use of a fluorescent tracer.
Ag+Ab..-Ag : Ab (Free fraction) k 2 (Bound fraction)
where Ag represents the antigen, Ab the antibody, and Ag : Ab the bound complex. At equilibrium, some of the free reactants will be combining, with a rate constant k l, to form more of the complex, while some of the complex will be dissociating, with a rate constant k 2 , to give free antigen and antibody.
Immunoassays are most commonly employed to quantitate antigens in biological fluids, and it is with this role that the present review is primarily concerned. Nonetheless, it should be noted that immunoassays are also frequently used to detect the presence of circulating antibodies or immune complexes. Indeed, Berson and his colleagues' pioneer work in radioimmunoassay followed their use of 13lI-labelled insulin to demonstrate the presence of circulating antibodies in patients treated with insulin.'
Basis of ffuorescenee and Ouorimetry
A body that emits light because of its high temperature is said to exhibit incandescence while all other forms of light emission are called molecules also explains the wide applicability of immunoassay. The labelled antigen or antibody in RIA or IRMA is employed only as a tracer, and any label is suitable provided its determination is relatively simple and sufficiently sensitive for the purpose of the assay and means are available to link covalently the label to the antigen or antibody.P It is not surprising, therefore, that many different materials have been employed for labelling purposes. Thus, in addition to beta-(3H,14C) and gamma-(l25I,57Co) emitting isotopes, these include enzymes,14-16 the coenzymes NAD1718 and ATp19 (detected by enzyme cycling-" or bioluminescent-s P systems), viruses,20 21 fluorescent and chemiluminescent'" molecules, proteins,23 metals,24 free radicals." red blood cells 26 and latex and other particles." While we have studied many of these alternative labels, recent work has been concentrated on the use of fluorescent molecules-for reasons that will become apparent. immunoradiometric assay for an analyte with two antigenic determinants. Antibody A, attached to a solid phase, is directed against one determinant, and antibody B, which is labelled with 126 1, is directed against the other. (b) Representation of a two-site 'sandwich' immunoradiometric assay employing a common label. It is similar to Fig. la except that antibody A, in addition to being directed against a different antigenic determinant from antibody B, is from a different species and neither is labelled. For example, antibody A may be raised in a sheep and antibody B in a rabbit. In such a situation a third antibody C labelled with 125 1 would be added, which is directed against rabbit immunoglobulins.
IMM UNOASSA YS EMPLOYING LABELLED ANTIBODIES
In 1968 Miles and Hales introduced an important new type of immunoassay which they termed immunoradiometric assay (IRMA), 7 8 based on the use of isotopically labelled specific antibodies.
IRMA differs markedly from RIA as an analytical technique. In the standard procedure only two, not three, reactants are required. Excessive amounts of labelled antibody are added to ensure that all the antigen is bound, so that IRMA can be defined as a 'reagent excess' as distinct from a 'limited reagent' procedure, which shortens incubation times and potentially improves sensitivity," It is necessary to separate the antibody (as opposed to the antigen) in the bound from that in the free fraction, and, finally, the counts in the bound fraction are related directly to the total amount of antigen present.
'Sandwich' techniques have also been developed for large molecules with more than one antigenic determinant-an approach pioneered by Wide and his colleagues," Thus, for example, in sandwich IRMA for human growth hormone'? the standard or unknown is first incubated with excess of an antibody linked to an insoluble support and directed against one antigenic determinant. After careful washing, excess of a second, isotopically labelled antibody directed against another part of the molecule is added ( Fig. la) . Subsequently, this approach has been further modified by use of a common, isotopically labelled second antibody'! ( Fig. lb) ,
NON-ISOTOPIC IMMUNOASSAYS
The dominant reactant in all immunoassays for antigens is the antibody since it is this which, in large part, determines the specificity (which is a feature of the close 'fit' necessary for all antigen: antibody reactions) and ultimate sensitivity that can be attained, the latter depending on the avidity with which the antibody binds the antigen. 612 The ability to raise antisera against an enormous range of circulating carrier proteins as the binding protein.
His use of the general term 'limited reagent methods' was to indicate that the concentration of binding protein must be insufficient to bind all the ligand."
The labelled antigen is employed as a tracer to enable determination of the distribution of total antigen (both labelled and unlabelled) between the antibody bound and free fractions. If the amounts of labelled antigen and of antiserum are kept constant, then the percentage of the counts present in the bound fraction is inversely related to the initial amount of unlabelled antigen present in the standards or samples being assayed.
luminescence. Fluorescence is one form of luminescence, the term being applied by Sir George Stokes, in 1852, to the, blue-white light observed in the mineral fluorspar (from the Latin fiuo-to flow). There are several different types of luminescence which differ only in the source of energy involved in exciting the molecule to a higher electronic state from which light may be emitted as it returns to the ground state. These include radioluminescence, with energy supplied by high energy particles; chemiluminescence, in which the energy is derived from a chemical reaction, this being referred to as bioluminescence if the reaction involves, or takes place in, a biological system; and, finally, photoluminescence involving excitation by photons (units of electromagnetic radiation) of infrared, visible, or ultraviolet light.
Thus it may return to the ground state by nonradiative 'internal conversion' and 'intersystem crossing' or by one of two light-emitting processes, namely: (a) fluorescence, in which the release of energy occurs in the form of a photon of longer wavelength; (b) phosphorescence, in which the release of energy is delayed and occurs via the triplet state.
The ultraviolet and visible regions of the spectrum are those of interest in fluorimetry. The energy associated with radiation of this frequency is quite high, being sufficient to cause breakdown of some absorbing molecules. The efficiency with which the excited molecules dissipate the energy by emission of light of a longer (and, therefore, less energetic) wavelength, the quantum yield, is defined as the number of quanta emitted/the number of quanta absorbed. This never exceeds unity.
Endogenous fluorophares
A background signal can also be caused by compounds present in the sample which themselves fluoresce when excited by light of the same wavelengths as the fluorophore employed as the label.
Among the ways in which a fluorescence signal can be decreased are:
SOME PROBLEMS IN FL UORESCENCE
Various factors present in biological fluids can cause an apparent increase or decrease in the fluorescence exhibited by a fluorophore. Examples include:
Light scattering
The incident beam of light can be scattered either from molecules (Rayleigh scattering) or from small particles in colloidal suspension (Tyndall scattering) and, thereby, summate with fluorescence--especially if the latter takes place at a wavelength close to that of the exciting light (as with a fluorophore having a small Stokes' shift). The loss of some of the incident light energy into vibrational and rotational energy of the solvent molecules may result in Raman scatter bands at wavelengths slightly longer than that of the exciting light. In photoluminescence, a photon of the appropriate energy (wavelength) excites the molecule from its ground state (SO> to a higher electronic state (Sl' S2' etc), in which the outer atomic electrons remain paired but one is promoted to a higher energy level. The luminescent properties of a molecule depend on the fate of the S1 species ( Fig. 2 
Inner filter effects
These are due to the presence of compounds which absorb part of either the excitation or emission beam.
Quenching
Many changes in the environment of a fluorophore can give rise to changes in the quantum yield of its fluorescence. This is termed quenching when the fluorescence signal is decreased and can be caused by such factors as a rise in temperature, changes in pH or polarity, or the presence of trace-oxidising agents Europium (Ill) (acetylocetonote) 3-(o-phO'nantrroli"") 256 or dissolved oxygen. Interaction of the fluorophore with specific quenching species (including organic materials such as tryptophan and iodine-containing molecules) can impair fluorescence, as can specific or non-specific binding to antibodies and to albumin, respectively. Another mechanism, termed resonance energy transfer, is discussed later as one approach to non-separation FIA and IFMA.
In assays on serum samples employing a fluorescein label, the interfering factors, in order of importance, are the presence of endogenous fluorophores, in particular bilirubin; light scattering by high concentrations of lipids and other large complexes; inner filter effects due to haemoglobin and bilirubin; and quenching due to non-specific binding by albumin.
CHOICE OF FL UOROPHORE
Among the fluorescent molecules most frequently used in immunochemistry are fluorescein and the rhodamines. Recently, there have been reports of the use of some umbeIliferones and rare earth chelates. Their structure is shown in Fig. 3 and some of their important characteristics in Table 1 .
Fluorescein is currently the label of choice in FIA and IFMA. Thus, in the dianion form, which predominates in aqueous alkaline solution, it has a quantum yield approaching the maximum possible and a high peak extinction coefficient for the absorption of radiation; its fluorescence may be excited by a variety of common light sources, and the green emission is well detected by conventional photomultipliers; it shows little photolability under normal fluorimetric conditions; its temperature coefficient is low; labelling techniques are relatively simple; and the labelled product has a virtually indefinite shelf-life and retains most of the quantum efficiency of the fluorescein molecule.
On the debit side, fluorescein has a small Stokes' shift with absorption and emission maxima of about 490 om and 520 om, respectively. Thus, light-
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Umbelli""one scattering interference could be a problem were it not for the availability of excellent dedicated filter systems. Of more importance, the absorption and emission bands occupy similar spectral regions to those of bilirubin; some fluorescein-labelled haptens bind non-specifically to albumin; and, finally, the close proximity of several fluorescein groups on a molecule results in 'concentration quenching' of the fluorescence.
FLUORIMETRY
An important difference between colorimetry and fluorimetry is that while the fraction of a parallel beam of light absorbed by a sample is independent of the intensity and relates directly to the concentration of the absorbing species (the Beer-Lambert law), the intensity of fluorescence emission is directly proportional to the intensity of the incident light. In addition, colorimetry involves the comparison of the similar intensities of two light beams (the sample beam and the reference beam), while in fluorimetry the sample is, in principle, detected against a zero background. This explains why fluorimetry is a much more sensitive procedure, able to detect down to about 10-1 4 moles using conventional equipment, as compared with colorimetric measurements which are able to detect only about 10-8 moles.
In a conventional fluorimeter, a solution of fluorescent molecules is excited with a light of constant intensity and appropriate wavelength. Within a microsecond a steady state is reached, the rate at which the fluorophores are being excited to higher electronic states being balanced by the combined rates of radiative (fluorescent) and nonradiative deactivation.
The components of a typical fluorimeter are shown in Figure 4 . The instruments can be divided into spectrophotofluorimeters and filter fluorimeters, depending on the means employed to isolate light of a desired wavelength in the excitation and emission light beams. The large, relatively expensive fluorimeters are of the former type and employ monochromators (usually based on a diffraction grating) to enable maximum versatility in wavelength selection. The latter employ optical filters of the absorbance or interference type, are less expensive, simpler to employ, and, provided the filters used are well-matched and of good quality, are as sensitive as spectrofluorimeters.
Various light sources, including lasers, can be employed, and for FIA and IFMA it is important to avoid even small variations in light intensity, since any fluctuations are reflected as an instability of overall fluorimetric efficiency. In order to overcome this problem fluorimeters of the 'ratio-recording' type have been introduced, in which the intensity of the light source is monitored independently and the fluorescence output is presented as the ratio of the fluorescence of the sample solution to the reference signal. Such (or similar) means of overcoming variations in light intensity are essential for the performance of reliable PIA and IFMA.
When fluorophores are employed as the label it is possible to introduce the assay tube directly, provided it is constructed of material that transmits both the exciting and emitted light; its walls are of uniform thickness; and there is a suitable holder to ensure the accurate location of the tube. A small flow-through cell, with a capacity of less than 100 ILl, is also suitable.
Comparison of Ouoroimmunoassay and radioimmunoassay
The impact of fluorophores as a label will depend upon their advantages and disadvantages compared with a gamma-emitting isotope such as iodine-125 (1 251). For convenience, only assays employing labelled antigen (FIA) and RIA will be considered since most of the conclusions reached also relate to labelled antibody techniques.
Oisplay unit Amplifier Fig. 4 The components ofa simple filter fluorimeter.
SIMILARITIES
Since the only fundamental difference between a FIA and a RIA is the label employed, it follows that they have much in common. Both are dependent on the production of suitable antisera in animals, and the same antisera can be employed for RIA and FlA. The same standards and quality control samples can also be used, and identical separation techniques are applicable. Thus the only difference in the immunoassay kits for ligands is the labelled antigen.
Most of the steps involved in a RIA and a FIA are also the same. Thus, in a conventional assay, it is first necessary accurately to pipette the sample (or standard), labelled antigen, and an approprate dilution of the antiserum into the assay tube, usually in microlitre volumes. The reactants must then be incubated until equilibrium has been reached, which may take from a few minutes (for compounds in the fLmol/1 range) to many hours (for compounds in the low pmol/l range), depending on the concentration of the reactants. It must be stressed, since there are claims to the contrary,28 that the time taken to attain equilibrium is unaffected by the nature of the label. The means for data reduction and the calculation of results are also identical, and the only steps that vary are the method of end-point detection and, in some instances, avoidance of the need to separate the antibody bound and free fractions.
Finally, many of the advantages of RIA are shared by FIA, including specificity, practicality, and wide applicability.
DIFFERENCES
Avoidance of health hazard
Considerable concern is often expressed about the radiation hazards associated with RIA.29 Care is essential in performing a radioiodination to produce the labelled antigen employed as the tracer, since several millicuries of 125 1 are commonly employed. However, performing a RIA involves the use of only about 0'1 fLCi of radioactivity, and there are no risks provided the most basic laboratory rules are followed. Nonetheless, some countries have so framed their legislation as to prohibit all but a few centres from performing RIA. Furthermore, there is an increasing emotive bias against the use of radioisotopes in most countries and, for example, few laboratory directors would let their female staff continue to perform such assays when pregnant. FIA and IFMA avoid these problems.
Preparation and stability of labelled reactant
Several excellent techniques have been developed to radioiodinate small and large antigens and antibodies both directly30-32 and by means of conjugation techniques. 3s-34 Fluorescein-labelling of proteins or of any molecules with a primary or secondary amino group is even easier, involving only their reaction with fluorescein isothiocyanate (FITC) at a slight alkaline pH. When the species to be labelled has no amino group, other simple methods are often available; for example, coupling of an oestrogen derivative by carbodiimide condensation with fluorescein amine. 35 When no suitable reactive group is available it may be possible to label a structurally related molecule. Thus ex, ex-diphenylglycine labelled with FITC gave a labelled product suitable for the development of FIA for phenytoin. 38 The main disadvantage of antigens (or antibodies) labelled with 125 1 or some other gamma-emitting isotope is their short shelf-life, usually limited to Smith, Al-Hakiem, Landon some six to 24 weeks. This reflects the short half-life of the isotope (about 60 days in the case of 1251), a progressive loss of immunoreactivity and of sensitivity of the assay, and acute changes due to decay catastrophe.V The short shelf-life necessitates frequent radioiodinations, which, in turn, significantly increase the cost of kit production, quality assurance (which must be performed with each new preparation), and distribution. It also means that some of the contents of a kit may remain unused and, therefore, wasted at the time of its expiry date. In contrast, antigens or antibodies labelled with a fluorophore have a virtually indefinite shelf-life ( Fig. 5 ). This is of inestimable value, especially from a commercial standpoint.
Variety of analytical approaches
RIA invariably requires a separation step before isotope counting because it is impossible to distinguish between the radioactivity in the antibody bound and free fractions. This step is often technically demanding, time-consuming, and one of the main sources of imprecision. Apart from the large number of different separation procedures available.P'' there is little opportunity to adopt different analytical approaches in a RIA. Thus, thyroxine wereprepared and used at the same time to set up standard curves for thyroxine. Similar results were obtained with that prepared in November 1974 and in November 1979. Seven additional batches had been prepared between these two dates and all behaved in a similar manner. This experiment illustrates the stability of FTC-thyroxine stored at -lOcC, the reproducible way in which it can be prepared, and its use in a fluoroimmunoassay which covers the hypothyroid, the narmal, and the hyperthyroid range. when the end-point determinations were performed in different polystyrene assay tubes, demonstrating that fluorimetry can be performed directly without transfer of the reactants into a cuvette.
Sensitivity
The main advantage of employing antigens labelled with a gamma-emitting isotope is that they enable attainment of the maximum possible sensitivity, which often lies in the low pmol/l range. This is set by the avidity with which the antiserum employed in the particular immunoassay binds the ligand, and the ability of RIA to achieve such sensitivity reflects three factors: the availability of methods to prepare labelled antigens of high specific activity, the efficiency of modem gamma counters, and, of especial importance, freedom from interference by biological fluids with end-point detection. This high signal to noise ratio is virtually unique to isotopes because biological samples do not contain any radioactivity, nor do they influence the efficiency of detection of gamma-emitting isotopes.
In contrast, as discussed earlier, biological samples contain many factors capable of interference with PIA and IFMA. It is this which explains why such assays have not, as yet, attained the sensitivity of RIA. Table 3 apart from conventional assays in which the sample (or standard), labelled antigen, and antiserum are added at the outset, the only common variant is to delay addition of the labelled antigen. Such so-called 'late addition' assays sometimes offer improved sensitivity."
The situation with regard to immunoassays employing a fluorescent label is quite different. Thus, as will be discussed in detail later, there are a plethora of different analytical approaches ( Dedicated filter fluorimeters are inexpensive although not yet so widely available in immunoassay laboratories as gamma counters. They are as simple to use and provide a result more quickly (less than 5 seconds) than the time taken to obtain a significant number of counts when an isotope is employed as the label. Fluorimetry is also one of the few are currently assayed by routine chemical means in a clinical chemistry laboratory circulate at levels in the mmol/l or !lmol/l range, as do many drugs (such as the aminoglycoside antibiotics and the anticonvulsants). Other drugs commonly determined by immunoassay, such as digoxin, methotrexate, and the tricyclic antidepressants, are active at nmol/l values.
Until recently, RIA was the only practical and widely available means for determining serwn levels of compounds present at nmol/l and pmol/l values. However, the advent of non-isotopic immunoassays has changed this situation, FIA being able to extend throughout the !lmol/l and nmol/l into the pmol/l range. Nonetheless, without some of the developments discussed later, they are about 10 times less sensitive than RIA.
Comparison of fluoroimmunoassay and other nonisotopic immunoassays
In several of the non-isotopic immunoassays (NIIA) summarised earlier, the complexity, time taken, and/or the insensitivity of end-point detection is such as virtually to exclude their extensive use at their present stage of development. These include NIIA employing viruses, free radicals, metals, proteins, and red blood cells as the label. Of the remainder, particles, enzymes, and chemiluminescent molecules would appear the main contenders to fluorophores as the label of choice and, because of their present extensive use, particular attention will be given to enzymoimmunoassay (EIA) and immunoenzymometric assays (lEMA).
SIMILARITIES
All types of NIIA share with FIA many similarities to RIA such as specificity and wide applicability; use of the same antisera, standards, and quality assurance samples; and many of the analytical steps. Several also share many of the advantages of FIA, including the stability of the labelled product; freedom from any health hazard or any emotive bias against their use; the potential for avoiding a separation step; and a large number of possible analytical approaches. Unfortunately, most NITA (like PIA but unlike RIA) experience problems with endogenous interfering factors in biological samples. For example, serum may contain enzymes with effects similar to those of the enzyme employed for labelling, and other factors, such as the presence of enzyme inhibitors or haemolysis, may influence the label's activity.
DIFFERENCES
There are some minor differences between EIA and FIA including:
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1 The large size of enzymes (as compared with fluorescein) limits the method of separating the bound and free fractions to solid phase and second antibody techniques. 2 It is necessary actually to separate the enzymelabelled antigen in the bound from that in the free fraction because, even when precipitated, enzyme activity will persist. In FIA it is necessary only to clear one or other fraction from the light path.
However, the single most important factor that differentiates the various types of NIIA and upon which future choice will be based is the means of end-point detection. Thus it seems logical to set out the criteria for an ideal end-point detection system (Table 4 ) and to assess how these are met by the various alternatives.
Use of fluorescent molecules or particles shares with gamma-emitting isotopes the advantage that immediate end-point measurement is possible after completion of the immunological reaction and the separation step (if required). In contrast, an additional chemical step is required when enzymes (and coenzymes) or chemilurninescent (and biolwninescent) molecules are employed. Thus, for example, the need to determine enzyme activity prolongs the assay, adds to its cost and complexity, and increases imprecision.P 43 From the standpoint of end-point detection, instruments for determining enzyme activity are the most widely available. However, in addition to the extra step required, the amplification made possible by use of an enzyme to attain sensitivity will also magnify any error; values are difficult to check; and a change in temperature of even l°C greatly influences enzymatic activity. In contrast, the temperature coefficient of fluorescein fluorescence is only -0,0035 per 0c. 44 At a time when there is general concern about the precision and be inexpensive and widely available in laboratories be simple to operate incorporate its own data-reduction microprocessor and printer The total detection system should:
be fast and suitable for automation provide precise results (with coefficients of variation less than I%) enable repeated checks of a result be very sensitive, necessitating a high signal-to-noise ratio be uninfluenced by normal or pathological samples accuracy of enzyme determinations in clinica chemistry it is perhaps surprising that most work in non-isotopic immunoassay has related to EIA.
Separation versus non-separation immunoassays
The development of EIA has followed two distinct directions. Most groups have followed the approach pioneered independently, in 1971, by Engvall and Perlmannv and by Van Weeman and Schuurs, 46 which the former termed enzyme linked immunosorbent assays (ELISA). Such assays include a separation step and are similar to RIA other than with regard to the label used and its means of endpoint detection. In contrast, the Syva Corporation has concentrated on developing highly innovative EIA which do not require separation of the bound and free fractions. Their range of assays, termed enzyme multiplied immunoassay techniques (EMIT) depend upon antibody binding either decreasing'" or increasingw the activity of the enzyme employed to label the antigen.
There is every indication of a similar dichotomy in the direction being taken by FIA and IFMA. Thus some groups routinely include a separation step, while others, with Syva to the fore, develop nonseparation assays. It is relevant, therefore, to consider the advantages of those two approaches.
ADVANTAGES OF NON-SEPARATION IMM UNOASSA YS
The first non-separation, non-isotopic immunoassay was described in 1953,49 some years before the introduction of RIA. Thus Arquilla and Stavitsky employed insulin labelled with erythrocytes in nonseparation procedures to detect circulating antibodies to insulin in treated diabetics and to assay nanogram amounts of insulin in buffer. 5O The assay was not sufficiently sensitive to apply to biological fluids, and little further attention appears to have been given to the subject until Leute and his colleagues" developed a successful non-separation assay for morphine in urine. It was based on the use of morphine labelled with a free radical and the change in electron spin resonance associated with antibody binding.
The separation step is often a matter for concern in an immunoassay. Thus it poses problems in the development of fully automated systems ;52 many of the techniques used for separation are technically demanding and require considerable expertise; such a step may add considerably to the time taken to complete an assay, especially if multiple washes and centrifugation are required; and, of particular importance, it may be a major cause of imprecision. 53 It follows from the above that non-separation immunoassays are simpler, quicker, and potentially lmore precise and are easily adaptable to automation. They are ideally suited to therapeutic monitoring of drugs and other haptens which circulate in the !J.molfl and upper nmol/l range in relatively healthy subjects. Indeed, they would invariably be used in preference to separation immunoassays were it not for three important factors: 1 Some separation techniques, such as the use of antibody-eoated tubes, are so simple that their inclusion is irrelevant from the standpoint of the extra work and time involved. Others, including the use of antisera covalently linked to magnetisable particles.s" 55 combine simplicity and speed with the excellent precision inherent in solid phase methodology.P 2 Most non-separation techniques developed to date are applicable only to haptens as opposed to proteins and other large molecules. 3 Non-separation assays are prone to interference by many factors, other than the compound to be assayed, present in biological fluids. Thus, as mentioned earlier, non-isotopic immunoassays in general do not share the highly favourable signal to noise ratio characteristic of RIA and IRMA employing gamma-emitting isotopes as the label.
Non-specific interference is the main problem in non-separation assays since, for example, serum may contain inhibitors or potentiators of the enzyme employed as the label, or some of the endogenous enzymes may show some activity for the substrate used for the final measurement.57 The problems associated with the accurate quantitation of fluorescence in biological samples have already been discussed. Means of avoiding such problems, other than by including an appropriate separation step, include prior extraction of the sample, for example, by means of organic solvents in steroid assays; pretreatment of the sample to inactivate interfering factors; and, most commonly, use of very small sample volumes to keep the background signal to a minimum. Unfortunately, extraction or pretreatment adds to the complexity and time taken to perform the assay while small sample volumes limit sensitivity.
Of special concern is the possibility that samples from severely ill patients or patients with hepatic or renal dysfunction may contain unexpectedly high levels of interfering factors which influence the results of non-separation immunoassays without this being recognised. If there is a risk, however smaIl, of making a wrong diagnosis or of inaccurately determining circulating levels of a toxic or lifesaving drug, then such an assay should not be used.
ADVANTAGES OF SEPARATION IMMUNOASSAYS
The separation step can be employed both to separate the bound and free fractions and, of special importance in non-isotopic immunoassay, to remove all endogenous interfering factors before end-point detection of the label in one or other fraction. 58 As a result of this, much larger sample volumes can be assayed with a marked improvement in sensitivity. Thus while non-separation immunoassays are currently limited to the flomol/l and nmol/l range, separation EIA can determine compounds circulating at low pmol/l levels.
At present separation assays provide the methods of choice: 1 for the assay of proteins and other large molecules; 2 for the assay of compounds circulating at low levels when the sensitivity required necessitates use of relatively large sample volumes; 3 for samples from very ill patients or subjects with disorders which may cause elevated levels of interfering substances; 4 for biological samples, such as urine, that may have high levels of some interfering compounds; and 5 when it does not prove possible to develop a quick, simple non-separation assay.
Nonetheless, future developments in instrumentation and non-isotopic labelling will markedly decrease the background signal and/or increase that given by the label. As a result, non-separation assays will become possible for all compounds of clinical relevance, irrespective of their level, the health of the patient or the disease being diagnosed. Some of these developments relating to FIA and IFMA are considered in a later section.
Types of immunoassay employing fluorescent labels
These can be divided into FIA, which employ a labelled antigen, and IFMA based on the use of specific antibodies labelled with a fluorophore. Each can be further subdivided into separation and non-separation procedures, for which Rubenstein and his colleagues" have suggested the terms heterogeneous and homogeneous, respectively.
LABELLED ANTIGEN TECHNIQUES-WITHOUT SEPARATION
PIA not requiring a separation step can be divided into those in which the signal originates from the free fraction and others in which the signal is contributed by the antibody-bound labelled antigen. eo 61 Some of these are discussed below.
Enhancement fluoroimmunoassays
PIA based on enhancement of the fluorescence of the labelled antigen upon antibody binding are possible but unusual. In one study,62 fluoresceinlabelled T 4 was found to give an abnormally low fluorescence yield, probably because of intramolecular quenching of the fluorophore by the
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iodine-containing thyroxine moiety. Antibody binding resulted in a fourfold increase in fluorescence (presumably by inhibiting the quenching effect), which served as the basis of an FlA.
Direct quenching fluoroimmunoassays
In direct contrast to the above are FIA which depend upon antibody binding leading to a reduction of fluorescence (Fig. 6 ). If a limited amount of antiserum is incubated with labelled and unlabelled antigen, the amount of the labelled species that becomes antibody bound (and, therefore, the extent of quenching) will be inversely related to the amount of unlabelled antigen present. Elimination of the need to separate greatly simplifies the method technically, but account must be taken of the many factors in biological samples which may interfere.
Direct quenching PIA have been developed for determining serum levels of gentamicin'P and for other aminoglycosides (such as amikacins'' and netilmlcinss) which are among the simplest immunoassay methods yet devised. Such assays can also be fully automated employing standard Auto-Analyzer mcdules.s" The high circulating concentrations of these antigens (in the low !Lmol/l range) enable sufficient dilution of the sample to avoid interfering factors unless the patient is icteric. fluorescein-labelled species" 72 by such antisera causes virtually complete quenching. In this approach, which we term indirect quenching FIA68 73 and others have called fluorescence protection immunoassay.ts sample, labelled antigen, and antiserum are incubated until equilibrium is attained, when an excess of anti-fluorescein serum is added. This immediately binds to and quenches the fluorophores in the free fraction but, because of steric hindrance by the first antibody, is unable to bind the fluorescein groups in the bound fraction ( Fig. 7) which continue to fluoresce. Indirect quenching FIA have been developed for human albumin in serum, urine, and cerebrospinal fluid,73 and for human immunoglobulin G and placental lactogen.s" This approach has also proved suitable for the detection of circulating antibodies."
Alternative binding fluoroimmunoassays
Only a minority of antisera raised against a hapten, such as gentamicin, are suitable for direct quenching FIA. Thus most antisera bind the fluoresceinlabelled drug without influencing its fluorescence to a useful extent. Perhaps, more surprisingly, the indirect quenching approach (despite a comment to the contrary'") is seldom, in our experience, applicable to haptens. The fluorescein-labelled hapten behaves as other small bifunctional antigens formed by the covalent linkage of two different antigens, which have been shown to cross-link mixtures of antibodies against the twO. 7 6-- 78 The success of indirect quenching FIA for proteins (as opposed to haptens) probably reflects the multiplicity of their antigenic sites, with the several antibodies bound to those different sites effectively preventing binding of label by the anti-fluorescein serum added later.
However, a novel non-separation FIA approach has been developed for haptens using the same reagents as for an indirect quenching assay-with the important difference that the antibodies to the hapten and to fluorescein are incorporated into a complex. The principle of this 'alternative binding' FlA is illustrated in Figure 8 . The labelled hapten can bind to only one antibody, and if this is directed against fluorescein then fluorescence is decreased, whereas if it is directed against the hapten fluorescence is unimpaired. Unlabelled hapten competes only for the anti-hapten binding sites so that its addition results in more of the tracer becoming bound to anti-fluorescein with a decrease in signal."
Release fluorolmmunoassays
Another type of non-separation FlA, introduced by Burd and his colleagues.P involves the use of a non-fluorescent labelled antigen (for example, a derivative of umbelliferyl-~-galactoside) which releases a fluorophore when split by an appropriate hydrolytic enzyme. Steric hindrance by the antibody in the bound fraction inhibits the action of the enzyme so that only the free fraction contributes to the signal. Practical assays for determining serum levels of gentamicin,81 tobramycin.P and phenytoin'" have been described, but limitations to the general application of this approach may prove to be the considerable chemical expertise required for the design and synthesis of suitable labelled antigens. Furthermore, such assays involve an extra step, namely, addition of enzyme and measurement of rate of fluorescence increase, as compared with alternative non-separation FlA.
Fluorescent excitation transfer fluoroimmunoassay
This novel approach, introduced by the Syva Corporation, involves the use of one reactant labelled with, for example, fluorescein (F) as donor, and a second labelled with rhodamine (R) which acts as an acceptor-because of its overlap with the emission of fluorescein.s! In one form, the reaction can be represented as follows:
Ag-F+Ab-R ""'" ' Ag-F: Ab-R Upon excitation at the appropriate wavelength the free fraction will give a signal. However, the proximity of the fluorescein and rhodamine in the bound fraction results in up to 70 /~fluorescence quenching, due to energy transfer to the acceptor molecule by a dipole-dipole resonance mechanism. This is, in effect, equivalent to a direct quenching FIA and has been applied to the assay of both haptens and proteins. A further adaptation, in which highly purified antibodies are labelled with fluorescein and with rhodamine, is considered later in this section. Other pairs of donor and acceptor labels, such as fluorescamine and fluorescein.P may also be suitable.
Polarisation fluoroimmunoassay
This technique was introduced independently by two groups for the assay of biological compounds. 88 • 87 When a solution of fluorescent molecules is excited with polarised light, the polarisation of the emitted light will depend on the extent of random Brownian rotation of the molecules that occurs during the lifetime of their excited state (4 to 5 ns in the case of fluoresceinlabelled molecules'" 89). The smaller the labelled antigen the faster will be its random rotation, reflected by a low signal. Binding by the large antibody molecule is equivalent to an increase in effective size and results in an enhanced signal. 
immunoassay. (A) When a fluorescein-labelled hapten is
incubated with a complex of antibodies against the label and the hapten some will be bound to the anti-hapten and continue to fluoresce while some will be bound by the anti-fluorescein with a resultant quenching offluorescence. (B) If unlabelled hapten is also present then this will compete for sites on the anti-hapten immunoglobulins so that more labelled hapten will be bound by anti-fluorescein with a further decrease in fluorescence. lJ~A spirote sUpl!rnote con-. .
tairing " -tracer and endogenous fluorophore to waste Fig. 9 Representation of a simultaneous addition fluoroimmunoassay in which the free fraction and interfering factors are aspirated (or decanted) to waste and the bound fraction eluted from the antibodies covalently linked to magnetisableparticles.
that is required is the application of a magnetic field. Furthermore, it is possible merely to sediment the particles to the bottom of the cuvette or assay tube and to read the fluorescence directly in the supernate.l'" 108..
.. 
Simultaneous addition, separation fiuoroimmunoassays
These are analogous to conventional RIA in that they involve addition of sample (or standard) and limited amounts of fluorescein-labelled antigen and antiserum. In one system, employed for the assay of thyroxine (T4) and triiodothyronine (T 3)' the antisera are covalently linked to small (2 to 5 microns) polyacrylamide beads. After incubation, the tubes are centrifuged and the supernate (containing the free fraction, endogenous fluorophores, and other interfering factors) is aspirated to waste. The beads are then resuspended and the fluorescence bound to them is measured directly.l04
In our approach (Fig. 9) , which employs antisera LABELLED ANTIGEN TECHNIQUES-WITH SEPARATION One of the first separation PIA was for human gamma globulin.P! Our group has developed such assays for determining serum gentamicin levels, using an ammonium sulphate separation step and measurement of the free fraction of the fluoresceinlabelled antibiotic in the supemate.l'" and serum phenytoin levels, using a sodium sulphate separation step followed by measurement of either the free fraction (in the supernate) or the bound fraction (in the precipitate) after it had been redissolved in NaOH.l03
The separation step has two important functions: first, to separate the antibody bound and free fractions and, second, to allow removal of any fluorophores or other interfering substances present in the sample before end-point detection. This second function enables the assay of larger serum volumes and markedly increases sensitivity provided there are adequate wash steps. In order to facilitate the latter and attain maximum precision," while keeping work to a minimum, there has been extensive use of solid-phase technology. Thus antibodies have been covalently bound to polyacrylamide beads l04 and to magnetisable particleslo.'>--lll or immobilised on the surface of a special paddle.l" Use of magnetisable particles avoids the need for (and is much quicker than) centrifugation since all The principle of polarisation FIA has been demonstrated in several assay systems for both haptens 36 88 DO 91 and proteins." 88 87 92 Assays of practical clinical applicability have been developed for urinary human chorionic gonadotrophin'< and serum levels of gentamicin." phenytoin,38 cortisol (with 95 or without'" an initial extraction step), neocarzinostatin'" and angiotensin I in an assay for plasma renin activity.u8 The technique has also been applied for the study of antibodies to penicillin." conalburnin.P? insulin.f? and neocarzinostatin'" by measurement of the increase in fluorescence polarisation employing fluorescent-labelled antigens.
Polarisation FIA is simple, quick, and precise. However, it has some major disadvantages. Tht: first, and most important, obstacle to its wider use it he lack of availability of convenient, relatively inexpensive, specially constructed polarisation fluorimeters capable of providing a direct readout. Second is the sensitivity, limited to the !Lmol/l and upper nmol/l range with respect to antigens in biological samples, and, finally, a lack of applicability to antigens with a molecular weight above about 20 ()()() because it depends upon the detection of a marked increase of effective size following antibody binding. Others have employed more conventional separation techniques for the FIA of human placental lactogen (HPL),llS gentamicin.P" and tobramycin'P in serum and of alpha-fetoprotein in amniotic fluid.H°Assays for 51X-dihydrotestosterone and oestradiol-l Zji employing poly-fluorophore-labelled steroids (see below) have also been described.P? An excess of antiserum covalently linked to magnetisable particles (as opposed to the limited amount employed in a conventional FIA) is incubated with sample (or standard) until all or most of the antigen has been bound, which is relatively quick because of the antiserum excess. The particles are then sedimented by brief application of a magnetic field, and the supernate, containing interfering compounds, is aspirated to waste ( Fig. 11 ). An excess of fluorescein-labelled antigen is now added, some of which is bound to the remaining unoccupied antibody sites while the remainder, left in the supernate, is read, the reading being directly related to the antigen content of the initial sample.
An example, for T4' was shown earlier (Fig. 5 ) with the standard curve covering the hypothyroid, euthyroid, and hyperthyroid ranges. Results correlate closely with those of a RIA and precision is good. IDS Sequential addition, separation PIA have also been developed for HPL and, of particular note because of the sensitivity achieved (less than 0·5 ng/ml), for digoxin.
10)
Endogenous
Magnetizable fluoraphore particle antibodỹ~1 ·J + r~J . .lJJ Inelbate labelled antibody is added in excess, and that bound to the solid phase, via the antigen, gives a direct measurement of the amount of the analyte. Quantitation can be achieved after elution of the labelled antibodies from the solid phase as in an assay for human IgG.l21 Alternatively, techniques have been developed that permit direct fluorimetry of bound fluorescent antibody on the solid phase. One approach, which depends on the use of a polyacrylamide bead support with carefully controlled refractive index and suspension properties,104 has been applied to the determination of the complement components C3 l22 and C4,123 IgG, 19A, and IgM 124 and C-reactive protein 126 in human serum and of IgGl28 and IgM127 in cerebrospinal fluid. Antibodies have also been immobilised on the plane surface of a polymethylmethacrylate film, bound labelled antibodies being measured using microfluorimetric apparatus.l'" The commercial 'FlAX' system employs antigen adsorbed on a cellulose acetate/nitrate disc attached to a plastic paddle ('StiQ' samplerj.P'' 129 Antigen is incubated with an excess of fluorescein-labelled antibody, and the StiQ is introduced to bind the remaining unreacted antibody. After washing, the fluorescence bound to the surface of the disc is measured in a specially designed fluorimeter.Ps The method has found most extensive use in the determination of IgG, 19A, and IgM in human serum. 124129 It is also suited to the detection of antibodies.ISO Similar assays have been demonstrated using antigens immobilised on polymethylmethacrylate film. 12 8 Relative to the sandwich approach, the use of antigenic solid phase has the advantage of permitting the IFMA of haptens. Ekeke and his colleaguesv" developed an IFMA for oestradiol-TZji employing steroid covalently linked to Sepharose particles and immunospecifically purified antibodies labelled with an umbelliferone derivative. and separation of the bound complex from excess unreacted labelled antibody by centrifugation'P 119 or filtration.P' It is of interest to point out that these reports preceded the first descriptions of the IRMA technique? 8 by several years. Recent work related to quantitative IFMA has involved the use of solid phase methods, employing either immobilised antibody (sandwich assays) or antigen. In the sandwich approach, excess antibody attached to a solid phase is first used to bind all the antigen from the sample. After washing, fluorescent-LABELLED ANTIBODY TECHNIQUES-WITHOUT SEPARATION All the labelled antibody techniques so far described have required a separation step. However, Ullman and his colleagues'" have successfully developed a non-separation IFMA based on fluorescent excitation transfer for large antigens, such as proteins, with more than one antigenic determinant. Thus one population of antibodies directed against human IgG was labelled with fluorescein (F) and another population with rhodamine (R). When an excess of both were added to the sample Ag+Ab-R+Ab-F ..==----'-Ab-R : Ag : Ab-F only the free fractions fluoresced fully, quenching in the bound fraction resulting from energy transfer from the donor (F) to the acceptor (R). This differs from the excitation transfer FIA described earlier in that only labelled antibodies and not labelled antigen are employed.
The binding of antigen by a fluorescent N-(3pyrene)maleimide conjugate of antibody directed against human IgG was observed to result in a significant enhancement of fluorescence.W This unusual effect was large enough to serve as the basis for a non-separation assay of IgG in serum.
Spatially selective excitation of fluorescence provides another means of avoiding the conventional separation step.133 Light undergoing total internal reflection at the quartz side of a quartz-water interface penetrates into the aqueous medium to a depth of only a few hundred nanometers. Thus if antigen is attached to the quartz surface and then fluorescent-labelled antibody is added to the aqueous medium, that bound to the antigen may be excited while unreacted labelled antibody will not encounter the exciting light and will not, therefore, fluoresce. If unlabelled antigen is present in the aqueous medium, the amount of labelled antibody available for binding to the quartz surface will be reduced. Assays for the phenyl arsonic acid and morphine haptens have been demonstrated using this approach.P''
Anticipated developments
DEVELOPMENT OF NEW FLUOROIMMUNOASSAYS
The next decade should witness a rapid increase in the range of FIA available as new assays are developed and they begin to replace some existing RIA. For analytes (such as serum specific proteins and many drugs) which circulate in the !J.mol/l range, non-separation assays may become the norm. For those in the nmol/l range. more sensitive separation FIA will be required, and areas of particular interest include steroid endocrinology and the replacement of existing activity measurements for enzymes and isoenzymes by FlA. Another potential area for expansion is in the PIA of compounds, such as cholesterol, which circulate in the mmol/I range.
DEVELOPMENT OF MORE SENSITIVE FLUOROIMMUNOASSAYS
In order to improve sensitivity it is necessary either to increase the signal given by the labelled reactant or to decrease background signals.
Poly-fiuorophore-labelling Increase of signal might appear to be relatively easily achievable by the attachment of many fluorophores to each labelled molecule, for example, by means of Smith, Al-Hakiem, Landon polylysine'F 134 or polyethyleneimine'P" 138 polymer chains to which up to several hundred fluorescent groups may be covalently bound. However, 'concentration quenching,' which occurs when fluorescein molecules are assembled in close mutual proximity,l38 137 severely limits the usefulness of this approach when conventional fluorimetry is employed for end-point detection. Thus the maximum fluorescence signal obtainable from a fluoresceinsubstituted polyethyleneimine polymer was equivalent to that of only two free fluorescein molecules and was achieved at a degree of substitution of about one fluorescein group per 14 polymer backbone units. l38 There is some evidencev" that the umbelliferone fluorophores are not as susceptible as fluorescein to concentration quenching. Steroids labelled with umbelliferonesubstituted polylysine chains were used as tracers in FIA systems that were as sensitive as corresponding RIA employing tritium-labelled tracers.P?
Hirschfeld-P" 136 showed that the problem of concentration quenching in poly-fluoresceinlabelling could be overcome by excitation to complete photochemical bleaching with the use of high-intensity laser illumination. He demonstrated both theoretically and experimentally that the bleaching lifetime of a fluorophore is inversely proportional to its fluorescence lifetime (hence also inversely proportional to its quantum yield of fluorescence). It follows that the total number of photons emitted by an average fluorophore as it passes through repeated excitation/emission cycles before being irreversibly destroyed by photochemical reaction is independent of its quantum yield ('quantum yield independent fluorimetry'). With illumination of sufficiently high intensity, bleaching may be achieved within milliseconds, even for polyfluorescein-substituted polymers with very low quantum yield, during which time each individual fluorophore emits the maximum possible number of photons. Single antibody molecules labelled with fluorescein-substituted polymers may be detected using this technique.P" In another approach it was shown that the detection sensitivity of poly-fluorescein-substituted polylysine could be increased by the use of a 'backtitration' method involving antibodies to fluorescein.P" After addition to the polymer of an excess of the antibodies, the remaining unbound antibodies are determined by the addition of a monomeric (and hence highly fluorescent) fluorescein species and measurement of the extent of quenching due to antibody binding. 68-73 The final signal is directly related to the initial amount of polymer. This approach has the advantage of requiring only conventional fluorimetric apparatus.
The increasing adoption of IFMA techniques in preference to labelled antigen methods is foreseen because, in addition to the other advantages of the use of labelled antibodies (see above), it is possible to introduce several molecules of fluorescein into the relatively large IgG molecule before concentration quenching becomes significant.137139 Even more important, at least 12 molecules of second antibody may be attached to each molecule of a first antibody in 'indirect' or sandwich methods,ll0 141 and this presents the possibility of signal amplification using labelled second antibodies, which should extend IFMA sensitivity into the pmol/l range of circulating analytes.
Background discrimination by bleaching lifetime
If the bleaching lifetime of fluorescent background signals (due to endogenous fluorophores of reagents or samples) is significantly shorter than that of the label fluorophores, intense pulsed excitation with delayed detection may be used to improve the signal to background ratio. l42 This provides an elegant application for the poly-fluorescein-substituted polymer labels discussed above, which have low quantum yield and hence long bleaching lifetime. As an alternative to time-gated detection, a flow system may be used in which the observation window is smaller than the illumination window and slightly offset from it. l42 This was the arrangement used to detect single antibody molecules.P''
The fluorescence bleaching characteristics of human serum are complex, showing at least three components, of which one has a lifetime sufficiently long to restrict the usefulness of the bleaching lifetime discriminating technique in the presence ofserum. 142 It was estimated that only a three-to seven-fold improvement in sensitivity could be expected in such circumstances relative to non-time-gated detection.
Background discrimination by fluorescence lifetime
By similar reasoning, if the label fluorescence and the background fluorescence have different lifetimes, then pulsed excitation followed by appropriately time-discriminated detection may allow the rejection of the background. l42-145 Of especial interest in this respect are fluorescent chelates of rare earth metals. l44145 These species have unusually long fluorescence lifetimes in the microsecond range (as opposed to lifetimes in the low nanosecond range for typical organic fluorophores, which must be presumed to be the main contributors to background signals). Thus, using relatively simple pulsedexcitation, time-gated instrumentation.w the fluorescence from such chelates may be detected long after the background emission has decayed to negligible levels. In addition, the rare earth chelates have the attributes of very large Stokes' shifts l45 148 and (for appropriate combinations of metal and chelating ligand) high quantum yields of fluorescence.v" In an idealised model system, a detection limit of about 0·2 pmol/l, or about 0·2 attomoles in a 10 flol sample, of europium thenoyltrifluoroacetonate was observed. 144 Fluorescence lifetime discrimination permitted a reduction in background signal from solvents and sample containers of three orders of magnitude, and from plasma of four orders of magnitude.w' An important practical obstacle to the introduction of rare earth chelates as labels in PIA and IFMA is likely to be the development of means for their stable chemical attachment to antigens and antibodies. Some steps in this direction have been briefly discussed,144--148 but as yet no description of the use of rare-earth-Iabelled reactants in an immunoassay system seems to have appeared.
Conclusions
It is likely that the 1980s will continue to witness a rapid increase in demand for immunoassays with their extension into many further medical and non-medical fields. This reflects the potential sensitivity, specificity, precision, practicality, and, in particular, wide applicability of such assays.
The various types of immunoassay are, in general, complementary rather than exclusive with nonlabelled techniques likely to continue to dominate for the quantitation of serum specific proteins. Radioimmunoassay will continue to be used for situations in which precise results are required and sensitivity a requisite-such as for the assay of free hormones and tumour specific products and for neonatal screening. Enzymoimmunoassay will continue to play a significant role specially for qualitative and semiquantitative assays (for example, to detect circulating antibodies) where a visual colour change offers the simplest end-point.
Nonetheless it is probable that other non-isotopic immunoassays will exhibit the most rapid rise and take over part of the roles of both radioimmunoassay and non-labelled immunoassay. Thus one or more of the non-isotopic techniques will dominate therapeutic drug monitoring and other new areas of expansion and take over progressively many of the high volume assays. The speed, simplicity, and precision of end-point detection indicate that fluoroimmunoassay will play an increasingly important role, especially as improvements in methodology (such as multilabelling) and in instrumentation (such as time-resolved fluorescence) result in a marked improvement in the sensitivity that can be achieved.
